Thank you very much, and thank you for the materials as well.
With this agreement there has been a clear strategy of trying to balance innovation and the clients you represent bringing new drugs to market to help Canadians with encouraging a culture of innovation alongside the balancing of costs and certainty for the generic industry as well.
Perhaps both of you could comment on the dual litigation issue. Certainly the agreement has expressed bringing the right of appeal to the branded side to the member companies in your organization. Really, would not both sides benefit from more certainty? Now that the patent linkage system is enhanced and offers that protection to both sides of the industry, shouldn't that really be where rights are determined rather than through the second route of the Patent Act?
Being a former lawyer myself, I know that certainly the whole system was good for lawyers but not good for certainty. Could you perhaps both comment on the potential to bring efficiency?